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Background: Levels of haemoglobin A1c (HbA1c) and blood lipids are important determinants of risk in patients with
diabetes. Standard analysis methods based upon venous blood samples can be logistically challenging in resource-poor
settings where much of the diabetes epidemic is occurring. Dried blood spots (DBS) provide a simple alternative method
for sample collection but the comparability of data from analyses based on DBS is not well established.
Methods: We conducted a systematic review and meta-analysis to define the association of findings for HbA1c and
blood lipids for analyses based upon standard methods compared to DBS. The Cochrane, Embase and Medline
databases were searched for relevant reports and summary regression lines were estimated.
Results: 705 abstracts were found by the initial electronic search with 6 further reports identified by manual review
of the full papers. 16 studies provided data for one or more outcomes of interest. There was a close agreement
between the results for HbA1c assays based on venous and DBS samples (DBS = 0.9858venous + 0.3809), except for
assays based upon affinity chromatography. Significant adjustment was required for assays of total cholesterol
(DBS = 0.6807venous + 1.151) but results for triglycerides (DBS = 0.9557venous + 0.1427) were directly comparable.
Conclusions: For HbA1c and selected blood lipids, assays based on DBS samples are clearly associated with assays
based on standard venous samples. There are, however, significant uncertainties about the nature of these
associations and there is a need for standardisation of the sample collection, transportation, storage and analysis
methods before the technique can be considered mainstream. This should be a research priority because better
elucidation of metabolic risks in resource poor settings, where venous sampling is infeasible, will be key to
addressing the global epidemic of cardiovascular diseases.
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Cardiovascular diseases [1] are increasing particularly
rapidly in developing country settings with diabetes a
key determinant of risk [2]. Documenting the role of
dysglycaemia and other metabolic risk factors [3-8] can
be challenging in these countries because the infra-
structure and resources required to conduct research
are limited. For example, assays of glycosylated haemo-
globin (HbA1c) and blood lipids are usually done on
venous blood samples which can be difficult to collect,* Correspondence: eaff7299@uni.sydney.edu.au
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reproduction in any medium, provided the ortransport and store. The use of dried blood spot sampling
(DBS) [9,10] is one possible solution. DBS involves pricking
the participant’s finger with a lancet and collecting drops of
blood on a piece of filter paper. Samples are then dried and
placed in sealed plastic bags for transportation and storage
[11,12]. Compared to venous samples, collecting DBS re-
quires minimal training of staff, is cheaper, is safer, provides
for simpler transportation and is more acceptable to study
participants [12-15].
DBS samples are now widely used for measuring serum
antibodies, human immunodeficiency virus (HIV) loads
and blood hormone levels with good data to define the
comparability of results between analyses based upon DBS
and standard venous samples [11,14,16,17]. The absencetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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and blood lipids means that DBS samples are not widely
used in studies making assessment of cardiovascular risks.
The objective of this project was to synthesise the avail-
able evidence describing the comparability of findings for
assays of HbA1c and blood lipids based upon DBS samples
compared to standard venous samples.
Methods
This project was a systematic review and meta-analysis
done to define the association of findings for HbA1c and
blood lipids for analyses based upon standard venous
samples compared to DBS samples. This was a secondary
analysis of existing published data and no ethics review
was therefore required.
Search strategy
The Cochrane, Embase and Medline databases were
searched electronically during July 2012 using combinations
of the terms “dried blood spot”, “dried blood”, “DBS”, “filter
paper”, “triglycerides”, “triacylglycerides”, “HbA1c”, “glyco-
sylated haemoglobin”, “glycosylated hemoglobin, “glycated
haemoglobin”, “glycated hemoglobin, “cholesterol”, “high
density lipoprotein”, “HDL”, “low density lipoprotein”
or “LDL”. Additional studies were identified by a manual
examination of the reference lists of all studies identified
as eligible.
Eligibility criteria
Studies were eligible for inclusion if they directly compared
values generated from analyses based on DBS samples to
analyses based on venous samples. To be included, a study
had to report in the form of a regression equation an asso-
ciation for one or more of the specified outcomes. There
was no restriction on the type of study population.
Data extraction
Two independent observers (EA and PD) reviewed the
abstracts for eligibility and extracted standardised data into
a data collection sheet for eligible studies. The data sought
from each study were based upon a comparable prior
systematic review done in the HIV field [17] and included:
date of publication, study size, participant characteristics
and sample storage conditions. For each risk factor re-
ported upon we sought to identify the laboratory extrac-
tion method, biochemical assay method and regression
coefficient. Where available we also noted data describing
the stability of the DBS samples.
Outcomes
The outcomes studied in this overview were HbA1c,
total cholesterol, high density lipoprotein (HDL) chol-
esterol, low density lipoprotein (LDL) cholesterol and
triglycerides.Statistical analysis
The characteristics of included studies were summarised in
tabular form (Table 1). The linear regression coefficients
from each study were pooled separately for each risk factor
using a weighted least squares approach [18] to estimate an
overall coefficient. The same method was used to estimate
a combined intercept. This gave a relationship of the form:
DBS = bVenous + a where ‘b’ is the combined coefficient
and ‘a’ is the combined intercept. The synthesis of the









where the weight, wi = the number of participants in
study i, and bi and ai represent the coefficient and inter-
cept, respectively, for the regression line in study i.
Heterogeneity of the individual study estimates contribut-
ing to each meta-analysis was assessed using the Cochran’s
Q and I2 statistics. Subsidiary analyses were done to explore
the impact of assay method for the outcome of HbA1c.
Results
There were 705 records identified by the electronic search
for which abstracts were reviewed. Six further studies were
found by the manual search of reference lists for included
studies (Figure 1). One final study was found during
the review process. Sixteen studies were ultimately in-
cluded in the meta-analysis, 12 of which reported ne-
cessary data for HbA1c, 1 for triglycerides, 2 for both
triglycerides and total cholesterol and 1 for HbA1c, total
cholesterol and HDL (Tables 1, 2) [9,10,19,21-34]. One
other study of HbA1c was excluded because it did not
provide a regression equation [35] and one other study of
triglycerides was excluded because it did not provide the
sample size [34]. There were no studies reporting data for
LDL-cholesterol identified.
The total numbers of participants providing data were
1425 for HbA1c, 773 for triglycerides and 1093 for total
cholesterol. Study sizes ranged from 30 to 613 partici-
pants. The assay methods varied for HbA1c which in-
cluded immunoturbidimetric, high performance liquid
chromatography (HPLC) and affinity chromatography
assays but all studies measuring triglycerides, total chol-
esterol and HDL used colorimetry.
HbA1c
For HbA1c the summary regression (DBS = 0.9858
V + 0.3809) (Figure 2) showed close agreement between
analyses based upon the venous and DBS sampling
methods. There was, however, evidence of heterogen-
eity between the contributing regression lines for the
intercepts (Cochran’s Q-test p < 0.001 and I2 = 98%) but
not the slopes (p = 0.833 and I2 = 0%). Subsidiary analyses
Table 1 Characteristics and findings of included studies
N Diabetes Population source Mean (SD) of DBS values Regression equation
HbA1c
Anjali 2007 [19] 78 Yes - 9.45 (±1.86) DBS = 0.95 V + 1.4
Buxton 2009 [20] 115 - Hospital - DBS = 0.85 V + 0.81
Egier 2011 [9] 85 - - - DBS = 0.933 V + 0.4
Fokkema 2009 [21]* 93 - Community - DBS = 1.006 V - 0.092
Fokkema 2009 [21]* 88 - Community - DBS = 0.994 V + 0.057
Fokkema. 2009 [21]* 73 - Community - DBS = 0.987 V - 0.011
Gay 1990 [22] 58 Yes Community 10.8 (±2) DBS = 0.8 V + 1.8
Jeppsson 1996 [23] 41 - - 7.49 DBS = 0.99 V + 0.16
Jones 2010 [10]* 73 - - 6.74 DBS = 0.984 V + 0.189
Jones 2010 [10]* 40 - - 8 DBS = 0.998 V - 0.204
Lacher et al. 2013 [24] 386 - Community 5.92 (±1.2) DBS = 0.94 V + 0.37
Lakshmy 2009 [25] 30 - Community 5.94 (±1.58) DBS = 0.9886 V + 0.0018
Little 1986 [26] 78 Yes/No - 10.2 DBS = 1.09 V + 2.17
Lomeo 2008 [27] 97 - - - DBS = 0.877 V + 1.09
Tabatabaei-Malazy 2011 [28]* 33 Yes Community 8.8 (±1.6) DBS = 1.20 V - 0.635
Tabatabaei-Malazy 2011 [28]* 33 Yes - 8.9 (±1.7) DBS = 1.25 V - 1.09
Wikblad 1998 [29] 145 Yes - - DBS = 1.03 V - 0.405
Triglycerides
Lakshmy 2010 [30]* 85 - Community 1.6 (±0.6) DBS = 1.028 V - 0.1690
Lakshmy 2012 [31]* 613 - Community 1.16 to 1.87 (±0.45 to 0.79) DBS = 0.9549 V + 0.1875
Quraishi 2006 [32] 75 - Community 1.297 (±0.53) DBS = 0.88 V + 0.13
Total Cholesterol -
Lacher 2013 [24] 395 - Community 3.76 (±0.87) DBS = 0.52 V + 1.08
Lakshmy 2010 [30]* 85 - Community 5 (±1) DBS = 0.727 V + 1.170
Lakshmy 2012 [31]* 613 - Community - DBS = 0.7779 V + 1.1943
HDL
Lacher 2013 [24] 395 Community 1.41 (±0.42) DBS = 0.7 V + 0.46
*Some studies provided multiple estimates and are repeated in the table. SD = standard deviation, DBS = dried blood spot, V = venous.
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tially attributable to different results for the two studies that
used affinity chromatography. Funnel plots did not provide
clear evidence of publication bias (Additional file 1: Figures
S1 and S2).
Blood lipids
The summary regression line for total cholesterol (DBS =
0.6807Venous + 1.151) (Figure 2) indicates a requirement
for moderate adjustment of values based upon analyses of
DBS samples to obtain estimates equivalent to standard
analyses based upon venous samples. The regression lines
for the two studies contributing to this meta-analysis were
directly comparable in terms of both slope and intercept
although both were derived from studies done at the same
investigational centre. For triglycerides, the summary re-
gression for the three contributing studies showed a closeassociation between the results obtained for the two
methods (DBS = 0.9557Venous + 0.1427) (Figure 2) without
any evidence of heterogeneity between the three results.
Only one data set was available for HDL.
Storage
Data about the circumstances and duration of storage of
DBS samples were inconsistently reported with few data
to describe whether the analysis findings were affected
by extended storage duration or different storage tempera-
tures. From the limited data available it was concluded that
DBS samples collected for assay of HbA1c and intended
for HPLC analysis can be stored for 5 days at room
temperature or for up to 3 years at −70°C [9,11,23]. If
analysis by immunoturbidimetry is planned, the data
variously suggest that samples can be stored safely at
room temperature for up to 44 days [10], at 4°C for up
Figure 1 Flow chart detailing identification of studies [36].
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[33]. For total cholesterol samples were reported as stable
for up to 1 month at room temperature [30,32] and up to
3 months at 4°C [32], and for triglycerides up to 1 month
at room temperature and up to 2 months at 4°C [30].
Discussion and conclusion
These analyses identified clear associations between assay
results based upon blood samples collected using trad-
itional venous approaches and blood samples collected
using DBS techniques, for both HbA1c and selected blood
lipids. The data provide a strong rationale for the further
investigation of DBS sample collection techniques although
also serve to highlight a number of areas that require
further exploration before the method is considered
mainstream in this field. If, however, standards and cal-
ibrations can be agreed, as has been achieved in other
fields of research [23,31,37], the DBS method does ap-
pear to have significant potential to address the logisticalchallenges of venous sampling for studies of metabolic
risks in resource poor settings [17].
The differences between the intercepts of the regression
lines obtained for the various analytic methods used for
assay of HbA1c require careful consideration in terms of
their implications. If the variation is due to the analytic
method selected then it will be necessary to recommend a
standard approach for each analyte of interest. However,
while the analytic method is the obvious explanation for
the observed variation it is not possible to exclude alterna-
tive causes on the basis of the available data. For example,
other aspects of the preparation of the DBS samples such
as transportation and extraction were not standardised
across the different analytic methodologies and might also
be a cause of the differences noted.
The incomplete and summary nature of the data available
for analysis placed significant constraints upon the extent
to which the results could be explored in this overview.
In particular, measures of variance of the data were
Table 2 Methods of sample analysis in the different studies AC = affinity chromatography, TII = turbidimetric inhibition
immunoassay, Ion = ion exchange chromatography, HPLC = high performance liquid chromatography, HR = haemolysing
reagent, Col = colorimetry
Dried blood spot data collection details Assay methods
Drying Transportation Extraction method DBS Venous
HbA1c
Anjali 2007 [19] - - Anti-HbA1c antibody. TII TII
Buxton 2009 [20] - Special shipping Roche HbA1c HR. TII HPLC
Egier 2011 [9] - - Extraction buffer HPLC HPLC
Fokkema 2009 [21]* - - HR TII TII
Fokkema 2009 [21]* - Routine mail HR TII TII
Fokkema. 2009 [21]* - - TII TII
Gay 1990 [22] Yes Routine mail - AC Ion
Jeppsson 1996 [23] - Routine mail Triton X-100 buffer HPLC HPLC
Jones 2010 [10]* Yes - HR and anti-HbA1c antibody. TII TII
Jones 2010 [10]* Yes Special shipping HR and anti-HbA1c antibody. TII HPLC
Lacher 2013 [24] Yes Packed in dry ice Extraction buffer HPLC HPLC
Lakshmy 2009 [25] Yes - Anti-HbA1c antibody TII/HPLC TII
Little 1986 [26] Yes - Water AC AC
Lomeo 2008 [27] - - HR HPLC HPLC
Tabatabaei-Malazy 2011 [28]* Yes - - TII TII
Tabatabaei-Malazy 2011 [28]* Yes - - TII TII
Wikblad 1998 [29] - Routine mail Phosphate-citrate buffer HPLC TII
Triglycerides
Lakshmy 2010 [30]* - Packed in ice Methanol Col. Col.
Lakshmy 2012 [31]* Yes Packed in ice Methanol Col. Col.
Quraishi 2006 [32] Yes - Methanol Col. Col.
Total Cholesterol
Lacher 2013 [24] Yes Packed in dry ice Deionized water Col. Col.
Lakshmy 2010 [30]* - Packed in ice Methanol Col. Col.
Lakshmy 2012 [31]* Yes Packed in ice Methanol Col. Col.
HDL
Lacher 2013 [24] Yes Packed in dry ice Deionized water Col. Col.
*Some studies involved multiple samples and are repeated in the table.
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that weighting be done by sample size alone [18] with
consequent limitations upon the methodologies that
could be used to present uncertainty intervals around
both the individual studies and the summary estimates.
For example, we identified a possible relationship between
the regression parameters and the mean HbA1c of the
contributing studies suggesting that both the intercept
and the slope might change when HbA1c rises above 8%
(Figures 3 and 4). This implies a non-linear association of
venous with DBS sample results that might require a more
nuanced explanation than the simple linear regressions
provided here [9]. Removing the studies with high average
HbA1c levels from the meta-analysis resulted in a regressionline approaching parity (DBS = 0.9553 V+ 0.2566) and with
a reduced heterogeneity for both the slopes (I2 = 0%) and
the intercepts (I2 = 92%). However, whether this simply re-
flects a chance finding in the data, or a true variation of the
association by mean HbA1c level is still uncertain. Likewise,
several studies used the same patients for two rounds of
analysis [21,28] and there would therefore have been some
correlation between the findings for each. This would not
be expected to substantially change the parameter estimates
obtained but certainly would increase the uncertainty
around them. Our inability to create robust uncertainty
intervals around our estimates is the primary weakness
of this piece of work. Unfortunately the lipid analyses were
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Figure 2 Individual (solid) and summary (dotted) regression lines showing the associations between results for analyses based upon
dried blood spot (DBS) compared to venous (V) samples for haemoglobin A1c (HbA1c) analysed by any method (2A), HbA1c analysed
by specific methods (2B to 2D), triglycerides (2E) and total cholesterol (2E). - Thickness of line increases with sample size. Line length was
defined as ±1 standard deviation (SD) of the study (or overall) mean. Where the mean or SD of a study was not available the average for that
analysis was used.
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work in this area to generate reliable regression analyses for
use in the field.
On a more positive note, the association between re-
sults based on venous and DBS samples appeared to beconsistent at the levels of HbA1c at which diabetes
mellitus is diagnosed (HbA1c > 6.5% [38]). This implies
that DBS samples could already be used for determining
the presence or absence of diabetes with reasonable cer-























Intercept Values by mean HbA1c
Figure 3 The mean HbA1c values from the studies are compared with the regression intercept the study generated. The marker size is
proportional to study size.
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be less reliable.
Most of the studies reported some information about
DBS sample preparation, transport and storage but the
data were provided in diverse formats and were substan-
tively incomplete. While it appears likely that DBS samples
are stable for adequate periods of time this is an area

























Figure 4 The mean HbA1c values from the studies are compared with
proportional to study size.of standardised recommendations prior to widespread
roll out of the methodology.
The establishment of World Health Organization ‘’25
by 25” target for the prevention of non-communicable
diseases [39] has added urgency to the need for data
about the metabolic determinants of cardiovascular risk.
With more than three quarters of all chronic disease now
occurring in developing country settings, the introduction8 9 10 11 12
HbA1c (%) 
ent by mean HbA1c 
the regression coefficient the study generated. The marker size is
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required to inform government decision making is a prior-
ity [40]. DBS sample collection methods appear to have
great potential for the evaluation of cardiometabolic risk
factors at the population level [9,13,27] enabling data
collection at scale in areas previously unstudied [15].
There remain, however, important advances to be made
in defining standard methodologies and adjustments be-
fore the DBS sampling method is confirmed as a sound
proxy for traditional venepuncture samples for these
types of blood analytes.
Additional files
Additional file 1: Figure S1. Funnel plot of the HbA1c regression
coefficients. Figure S2. Funnel plot of the HbA1c regression intercepts.
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